Renaissance Technologies
PCVX icon

Renaissance Technologies’s Vaxcyte PCVX Stock Holding History

Renaissance Technologies’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Sell
19,634
-35,100
-64% -$1.91M ﹤0.01% 2251
2026
Q1 		$3.18M Sell
54,734
-10,477
-16% -$569K 0.01% 1634
2025
Q4 		$3.01M Sell
65,211
-15,266
-19% -$683K ﹤0.01% 1624
2025
Q3 		$2.9M Sell
80,477
-188,600
-70% -$6.25M ﹤0.01% 1821
2025
Q2 		$8.75M Buy
269,077
+72,800
+37% +$2.39M 0.01% 1144
2025
Q1 		$7.41M Buy
196,277
+142,200
+263% +$11.4M 0.01% 1181
2024
Q4 		$4.43M Buy
+54,077
New +$5.37M 0.01% 1522
2023
Q3 		– Sell
-215,477
Closed -$10.8M – 3977
2023
Q2 		$10.8M Sell
215,477
-205,400
-49% -$9.74M 0.02% 984
2023
Q1 		$15.8M Sell
420,877
-101,100
-19% -$4.29M 0.02% 849
2022
Q4 		$25M Buy
521,977
+428,777
+460% +$16.8M 0.03% 607
2022
Q3 		$2.24M Buy
93,200
+20,600
+28% +$522K ﹤0.01% 1944
2022
Q2 		$1.58M Buy
72,600
+31,800
+78% +$736K ﹤0.01% 2366
2022
Q1 		$985K Buy
40,800
+27,800
+214% +$607K ﹤0.01% 2735
2021
Q4 		$309K Buy
+13,000
New +$302K ﹤0.01% 3333

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Renaissance Technologies's PCVX Position: Q2 2026 in Review

Renaissance Technologies reduced its Vaxcyte (PCVX) stake by 64% in Q2 2026, selling an estimated $1.91M and leaving 19,634 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Renaissance Technologies first reported a position in PCVX in Q4 2021 and has held it in 14 quarters since. The position peaked at $25M in Q4 2022. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Renaissance Technologies held 19,634 shares of Vaxcyte worth $1.14M as of Q2 2026.
  • Renaissance Technologies sold 35,100 Vaxcyte shares in Q2 2026, an estimated $1.91M.
  • Vaxcyte made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2251 holding.
  • Renaissance Technologies first reported a position in Vaxcyte in Q4 2021 and has held it in 14 quarters since.
  • Renaissance Technologies's Vaxcyte position peaked at $25M in Q4 2022.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.